Frontline Acalabrutinib Plus Chemoimmunotherapy Elicits Mean

Acalabrutinib plus bendamustine and rituximab (BR) led to a statistically significant improvement in PFS vs BR for treatment-naive mantle cell lymphoma.

Related Keywords

Japan , Texas , United States , Houston , China , Acalabrutinib Calquence , Susan Galbraith , Michael Wang , Astrazeneca , University Of Texas Md Anderson Cancer Center , European Union , Mantle Cell Lymphoma Program Of Excellence , Puddin Clarke Endowed Professor , Mantle Cell Lymphoma Program , Cancer Center , Lugano Classification ,